HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
eNrFmN9v2jAQx9/5K6K8EydQSpgC1cbaDWnVGC3atBdkkqOYpXbqH0D3188hdKWTo66mVt9I7NydfV9/7nBytr3NvTVwQRjt+1EQ+h7QlGWE3vT96fVFM/bPBo1khdf4YJqeF7RavpfmWIi+X44Gc8BUBD8uv3wE/T1wf9DwEjZfQSqfzFOS5MFnLJaXuCjneMmakcy7BblkWd8vlNy99RIhuY5isGH8lyhwCgnavzkcXc1ODt8nqDT2H1aVAP4F0xujUaBWNlPFOVA5xBJuGL83ml6ks6jVCcO4Z+WCiAkIpngKYyyXY87WJIPM7AnnAqycLDbZFfB1DrJ0YjSOVumtsDKOV3g7gbuROej3enQot7IZNqNudNLudeJ2pxt1rFzxg60yi0cvAhWzdtg97fa6CCjKICWlxpu0FUa9Zhi1T1GWopVAOZmjJRFSJzbQj48/LfM4Zlzi3FEGiRg+1aIjPxzunlVKRkSR43KnCtutwhzrYeCaGO4WUq7gmmuG5XrP/rFPVZ6jF0Y93RPGUcQlwIZMUVkDmouJ7UYMGZWwrc+oHRvldq9FAuL1zP5m1FwXxmqek9QWfxpQCoScTkb19HsrcHzAAqbcHTm+E5qxjXh9Ih0qwFH0xQ6qRqMFz6JZqxefRp2O9YH7qeVWU7nOFWcFIM0qIo5B0Igu2LHw0Qo2m3rQ75tId9dysRTnUNN0zSyZpTX70CM6OxXuTlw1YDT66fzaVkrfFPD7q92j0TTJ+n9FYAd0F1VCC7c28Jcfg4oGz7Xjrbh7ErdjO0lzM2yWUhbiHUKbzSZYYtEUWG9WsOBvWjgO6rq7Pw5Omoeqmarg6yj0eVVVX5ZN28P5XHtxbMu8/37fmht9SK7giFxUHHdG29H56wP8sV92Fvb4CXDcudn1tlhqarjqo9Tc3EQdVTJ0XukF14D4uliQmvucWl0mqLpLGjQSVN4jDRp/AP+cI64=
0yDYERYN5Gpq5wmj